Form 4 for KRSA Korsana Biosciences, Inc.
Accepted 2026-08-18 17:27:18 ET · period of report 2026-08-14 · accession 0001193125-26-355721 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-18 17:27 | 2026-08-14 | KRSA | CHICKO RHONDA M. | CFO | M - OptEx | $2.35 | +25.0K | 25.0K | +138,889% | +$58.9K |
| D | 2026-08-18 17:27 | 2026-08-14 | KRSA | CHICKO RHONDA M. | CFO | M - OptEx | $0.00 | -25.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, no par value | 2026-08-14 | M | A | 25,000 | $2.35 | 25,018 | D | — | — | (F1) The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price. |
| 2 | Derivative | Option to Purchase | 2026-08-14 | M | D | 25,000 | $0.00 | 0 | D | $2.35 · — to 2035-08-06 | 25,000 Common Stock | (F1) The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price. (F1) The Reporting Person was granted an option on August 7, 2025 to purchase up to 25,000 shares of the Corporation's common stock pursuant to the Issuer's 2019 Equity Incentive Plan. These 25,000 shares provided for vesting as follows: (i) 8,750 shares became immediately exercisable, and (ii) the remaining 16,250 shares were to vest ratably in monthly installments commencing August 31, 2025 and ending on February 28, 2028, provided that the Reporting Person remained as a consultant or employee of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions. On July 17, 2026, the Issuer's Board of Directors elected to accelerate in full the vesting of all then unvested options for the Reporting Person. The Reporting Person exercised the option in full on August 14, 2026 and paid for the exercise by means of a cash payment to the Issuer for the full purchase price. |